Elvin Koh
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Elvin Koh has a total of 24 co-authors. Here are the top co-authors by number of shared publications:
- In Young Hwang
Department of Biochemistry, Yong Loo Lin School of Medicine, National University of Singapore, Singapore 117596, Singapore
3 shared publications - Matthew Wook Chang
NUS Synthetic Biology for Clinical and Technological Innovation (SynCTI) National University of Singapore Singapore Singapore
3 shared publications John C. March
Department of Biological and Environmental Engineering, Cornell University, Ithaca, USA
2 shared publications- Yung Seng Lee
Department of Paediatrics, Yong Loo Lin School of Medicine, National University of Singapore, Singapore
2 shared publications - Adison Wong
Food, Chemical and Biotechnology Cluster, Singapore Institute of Technology, 1 Punggol Coast Road, Singapore 828608, Singapore
1 shared publication Chueh Loo Poh
School of Chemical and Biomedical Engineering, Nanyang Technological University, 62 Nanyang Drive, Singapore 637459
1 shared publication
Latest Publications
- Open Access
- 4 July 2022
- Published by Springer Nature in Nature Communications
- Vol. 13 (1) , 1-13
Engineering probiotics to inhibit Clostridioides difficile infection by dynamic regulation of intestinal metabolism
Clostridioides difficile infection (CDI) results in significant morbidity and mortality in hospitalised patients. The pathogenesis of CDI is intrinsically related to the ability of C. difficile to shuffle between active vegetative cells and dormant endospores through the processes of germination and sporulation. Here, we hypothesise that dysregulation of microbiome-mediated bile salt metabolism contributes to CDI and that its alleviation can limit the pathogenesis of CDI. We engineer a genetic circuit harbouring a genetically encoded sensor, amplifier and actuator in probiotics to restore intestinal bile salt metabolism in response to antibiotic-induced microbiome dysbiosis. We demonstrate that the engineered probiotics limited the germination of endospores and the growth of vegetative cells of C. difficile in vitro and further significantly reduced CDI in model mice, as evidenced by a 100% survival rate and improved clinical outcomes. Our work presents an antimicrobial strategy that harnesses the host-pathogen microenvironment as the intervention target to limit the pathogenesis of infection.
- 4 July 2022
- Published by Springer Nature in Nature Communications
- Vol. 13 (1) , 1-13
Open AccessEngineering probiotics to inhibit Clostridioides difficile infection by dynamic regulation of intestinal metabolism
Clostridioides difficile infection (CDI) results in significant morbidity and mortality in hospitalised patients. The pathogenesis of CDI is intrinsically related to the ability of C. difficile to shuffle between active vegetative cells and dormant endospores through the processes of germination and sporulation. Here, we hypothesise that dysregulation of microbiome-mediated bile salt metabolism contributes to CDI and that its alleviation can limit the pathogenesis of CDI. We engineer a genetic circuit harbouring a genetically encoded sensor, amplifier and actuator in probiotics to restore intestinal bile salt metabolism in response to antibiotic-induced microbiome dysbiosis. We demonstrate that the engineered probiotics limited the germination of endospores and the growth of vegetative cells of C. difficile in vitro and further significantly reduced CDI in model mice, as evidenced by a 100% survival rate and improved clinical outcomes. Our work presents an antimicrobial strategy that harnesses the host-pathogen microenvironment as the intervention target to limit the pathogenesis of infection.
- Top Cited PapersOpen Access
- 11 April 2017
- Published by Springer Nature in Nature Communications
- Vol. 8 (1) , 15028
Engineered probiotic Escherichia coli can eliminate and prevent Pseudomonas aeruginosa gut infection in animal models
Bacteria can be genetically engineered to kill specific pathogens or inhibit their virulence. We previously developed a synthetic genetic system that allows a laboratory strain of Escherichia coli to sense and kill Pseudomonas aeruginosa in vitro. Here, we generate a modified version of the system, including a gene encoding an anti-biofilm enzyme, and use the probiotic strain Escherichia coli Nissle 1917 as host. The engineered probiotic shows in vivo prophylactic and therapeutic activity against P. aeruginosa during gut infection in two animal models (Caenorhabditis elegans and mice). These findings support the further development of engineered microorganisms with potential prophylactic and therapeutic activities against gut infections.
- 11 April 2017
- Published by Springer Nature in Nature Communications
- Vol. 8 (1) , 15028
Top Cited PapersOpen AccessEngineered probiotic Escherichia coli can eliminate and prevent Pseudomonas aeruginosa gut infection in animal models
Bacteria can be genetically engineered to kill specific pathogens or inhibit their virulence. We previously developed a synthetic genetic system that allows a laboratory strain of Escherichia coli to sense and kill Pseudomonas aeruginosa in vitro. Here, we generate a modified version of the system, including a gene encoding an anti-biofilm enzyme, and use the probiotic strain Escherichia coli Nissle 1917 as host. The engineered probiotic shows in vivo prophylactic and therapeutic activity against P. aeruginosa during gut infection in two animal models (Caenorhabditis elegans and mice). These findings support the further development of engineered microorganisms with potential prophylactic and therapeutic activities against gut infections.
- 1 July 2016
- Published by Elsevier in Drug Resistance Updates
- Vol. 27, 59-71
Reprogrammable microbial cell-based therapeutics against antibiotic-resistant bacteria
- 1 July 2016
- Published by Elsevier in Drug Resistance Updates
- Vol. 27, 59-71
Reprogrammable microbial cell-based therapeutics against antibiotic-resistant bacteria
- 13 September 2013
- Published by American Chemical Society (ACS) in ACS Synthetic Biology
- Vol. 3 (4) , 228-237
Reprogramming Microbes to Be Pathogen-Seeking Killers
Recent examples of new genetic circuits that enable cells to acquire biosynthetic capabilities, such as specific pathogen killing, present an attractive therapeutic application of synthetic biology. Herein, we demonstrate a novel genetic circuit that reprograms Escherichia coli to specifically recognize, migrate toward, and eradicate both dispersed and biofilm-encased pathogenic Pseudomonas aeruginosa cells. The reprogrammed E. coli degraded the mature biofilm matrix and killed the latent cells encapsulated within by expressing and secreting the antimicrobial peptide microcin S and the nuclease DNaseI upon the detection of quorum sensing molecules naturally secreted by P. aeruginosa. Furthermore, the reprogrammed E. coli exhibited directed motility toward the pathogen through regulated expression of CheZ in response to the quorum sensing molecules. By integrating the pathogen-directed motility with the dual antimicrobial activity in E. coli, we achieved signifincantly improved killing activity against planktonic and mature biofilm cells due to target localization, thus creating an active pathogen seeking killer E. coli.
- 13 September 2013
- Published by American Chemical Society (ACS) in ACS Synthetic Biology
- Vol. 3 (4) , 228-237
Reprogramming Microbes to Be Pathogen-Seeking Killers
Recent examples of new genetic circuits that enable cells to acquire biosynthetic capabilities, such as specific pathogen killing, present an attractive therapeutic application of synthetic biology. Herein, we demonstrate a novel genetic circuit that reprograms Escherichia coli to specifically recognize, migrate toward, and eradicate both dispersed and biofilm-encased pathogenic Pseudomonas aeruginosa cells. The reprogrammed E. coli degraded the mature biofilm matrix and killed the latent cells encapsulated within by expressing and secreting the antimicrobial peptide microcin S and the nuclease DNaseI upon the detection of quorum sensing molecules naturally secreted by P. aeruginosa. Furthermore, the reprogrammed E. coli exhibited directed motility toward the pathogen through regulated expression of CheZ in response to the quorum sensing molecules. By integrating the pathogen-directed motility with the dual antimicrobial activity in E. coli, we achieved signifincantly improved killing activity against planktonic and mature biofilm cells due to target localization, thus creating an active pathogen seeking killer E. coli.
- Open Access
- 27 March 2012
- Published by Public Library of Science (PLoS) in PLOS Biology
- Vol. 10 (3) , e1001290
Mediator Acts Upstream of the Transcriptional Activator Gal4
The proteasome inhibitor MG132 had been shown to prevent galactose induction of the S. cerevisiae GAL1 gene, demonstrating that ubiquitin proteasome-dependent degradation of transcription factors plays an important role in the regulation of gene expression. The deletion of the gene encoding the F-box protein Mdm30 had been reported to stabilize the transcriptional activator Gal4 under inducing conditions and to lead to defects in galactose utilization, suggesting that recycling of Gal4 is required for its function. Subsequently, however, it was argued that Gal4 remains stably bound to the enhancer under inducing conditions, suggesting that proteolytic turnover of Gal4 might not be required for its function. We have performed an alanine-scanning mutagenesis of ubiquitin and isolated a galactose utilization-defective ubiquitin mutant. We have used it for an unbiased suppressor screen and identified the inhibitor Gal80 as a suppressor of the transcriptional defects of the ubiquitin mutant, indicating that the protein degradation of the inhibitor Gal80, and not of the activator Gal4, is required for galactose induction of the GAL genes. We also show that in the absence of Gal80, Mdm30 is not required for Gal4 function, strongly supporting this hypothesis. Furthermore, we have found that Mediator controls the galactose-induced protein degradation of Gal80, which places Mediator genetically upstream of the activator Gal4. Mediator had originally been isolated by its ability to respond to transcriptional activators, and here we have discovered a leading role for Mediator in the process of transcription. The protein kinase Snf1 senses the inducing conditions and transduces the signal to Mediator, which initiates the degradation of the inhibitor Gal80 with the help of the E3 ubiquitin ligase SCFMdm30. The ability of Mediator to control the protein degradation of transcriptional inhibitors indicates that Mediator is actually able to direct its own recruitment to gene promoters. The expression levels of proteins are tightly regulated, not only via their production but also via their degradation. Genes are transcribed only if their encoded proteins are required by the environmental or developmental conditions of a cell, and once a certain protein is no longer needed, it is rapidly degraded by the ubiquitin proteasome system (UPS). Transcriptional activators appeared to contradict this simple economic principle, as it had been claimed that they had to be degraded in order to function. The claim was based upon a correlation: if the degradation of an activator was prevented by drugs or mutations in the UPS, the activator became stable but also nonfunctional. We have now shown that it is not the activator itself but its inhibitor that is the functionally relevant target of the UPS. Furthermore, we have found that the degradation of the inhibitor is controlled by a protein complex called Mediator. The activator is known to recruit Mediator to gene promoters, where Mediator assists RNA polymerase in initiating transcription. Mediator was always considered to be completely under the control of the activator; however, we observe that by regulating the degradation of the inhibitor, Mediator is also able to control the activator and thereby to orchestrate its own recruitment to gene promoters.
- 27 March 2012
- Published by Public Library of Science (PLoS) in PLOS Biology
- Vol. 10 (3) , e1001290
Open AccessMediator Acts Upstream of the Transcriptional Activator Gal4
The proteasome inhibitor MG132 had been shown to prevent galactose induction of the S. cerevisiae GAL1 gene, demonstrating that ubiquitin proteasome-dependent degradation of transcription factors plays an important role in the regulation of gene expression. The deletion of the gene encoding the F-box protein Mdm30 had been reported to stabilize the transcriptional activator Gal4 under inducing conditions and to lead to defects in galactose utilization, suggesting that recycling of Gal4 is required for its function. Subsequently, however, it was argued that Gal4 remains stably bound to the enhancer under inducing conditions, suggesting that proteolytic turnover of Gal4 might not be required for its function. We have performed an alanine-scanning mutagenesis of ubiquitin and isolated a galactose utilization-defective ubiquitin mutant. We have used it for an unbiased suppressor screen and identified the inhibitor Gal80 as a suppressor of the transcriptional defects of the ubiquitin mutant, indicating that the protein degradation of the inhibitor Gal80, and not of the activator Gal4, is required for galactose induction of the GAL genes. We also show that in the absence of Gal80, Mdm30 is not required for Gal4 function, strongly supporting this hypothesis. Furthermore, we have found that Mediator controls the galactose-induced protein degradation of Gal80, which places Mediator genetically upstream of the activator Gal4. Mediator had originally been isolated by its ability to respond to transcriptional activators, and here we have discovered a leading role for Mediator in the process of transcription. The protein kinase Snf1 senses the inducing conditions and transduces the signal to Mediator, which initiates the degradation of the inhibitor Gal80 with the help of the E3 ubiquitin ligase SCFMdm30. The ability of Mediator to control the protein degradation of transcriptional inhibitors indicates that Mediator is actually able to direct its own recruitment to gene promoters. The expression levels of proteins are tightly regulated, not only via their production but also via their degradation. Genes are transcribed only if their encoded proteins are required by the environmental or developmental conditions of a cell, and once a certain protein is no longer needed, it is rapidly degraded by the ubiquitin proteasome system (UPS). Transcriptional activators appeared to contradict this simple economic principle, as it had been claimed that they had to be degraded in order to function. The claim was based upon a correlation: if the degradation of an activator was prevented by drugs or mutations in the UPS, the activator became stable but also nonfunctional. We have now shown that it is not the activator itself but its inhibitor that is the functionally relevant target of the UPS. Furthermore, we have found that the degradation of the inhibitor is controlled by a protein complex called Mediator. The activator is known to recruit Mediator to gene promoters, where Mediator assists RNA polymerase in initiating transcription. Mediator was always considered to be completely under the control of the activator; however, we observe that by regulating the degradation of the inhibitor, Mediator is also able to control the activator and thereby to orchestrate its own recruitment to gene promoters.